In addition, our results showed that the IL-17A and IL-22 tissue level in the AD group and AD+M group on Day 11 and on Day 15 were significantly elevated than that of the control group and AD group (p < 0.001) (Figure 3a). This evidence concerns the gene IL22 and Alzheimer disease.